Sign in or create an account to add this stock to your watchlist.
About Repligen (NASDAQ:RGEN)
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies and recombinant proteins; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company provides filtration products, such as XCell ATF systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius TFF line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RGEN
CUSIP75991610
Phone781-250-0111
Debt
Debt-to-Equity Ratio0.17
Current Ratio12.22
Quick Ratio10.25
Price-To-Earnings
Trailing P/E Ratio61.17
Forward P/E Ratio59.45
P/E Growth2.84
Sales & Book Value
Annual Sales$141.24 million
Price / Sales13.06
Cash Flow$0.8572 per share
Price / Cash49.24
Book Value$13.58 per share
Price / Book3.11
Profitability
EPS (Most Recent Fiscal Year)$0.69
Net Income$28.35 million
Net Margins18.48%
Return on Equity6.06%
Return on Assets4.69%
Miscellaneous
Employees476
Outstanding Shares43,690,000
Repligen (NASDAQ:RGEN) Frequently Asked Questions
What is Repligen's stock symbol?
Repligen trades on the NASDAQ under the ticker symbol "RGEN."
How were Repligen's earnings last quarter?
Repligen (NASDAQ:RGEN) announced its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.02. The biotechnology company had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.88 million. Repligen had a net margin of 18.48% and a return on equity of 6.06%. The firm's revenue was up 46.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.15 EPS. View Repligen's Earnings History.
When is Repligen's next earnings date?
What guidance has Repligen issued on next quarter's earnings?
Repligen issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $0.69-0.73 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.70. The company issued revenue guidance of $182-188 million, compared to the consensus revenue estimate of $183.48 million.
What price target have analysts set for RGEN?
7 Wall Street analysts have issued 12-month price objectives for Repligen's shares. Their predictions range from $40.00 to $50.00. On average, they anticipate Repligen's share price to reach $44.5714 in the next year. View Analyst Ratings for Repligen.
Who are some of Repligen's key competitors?
Some companies that are related to Repligen include Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Repligen's key executives?
Repligen's management team includes the folowing people:
- Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 54)
- Mr. Jon K. Snodgres, CFO, Sec. & Principal Accounting Officer (Age 52)
- Mr. Steve Curran, VP of Global Operations
- Ms. Sondra S. Newman, Sr. Director Investor Relations
- Mr. Stephen Tingley, VP of Sales
Has Repligen been receiving favorable news coverage?
Media headlines about RGEN stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repligen earned a daily sentiment score of 0.21 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Repligen's major shareholders?
Repligen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.28%), OppenheimerFunds Inc. (4.55%), Dimensional Fund Advisors LP (2.32%), Federated Investors Inc. PA (2.13%), Stephens Investment Management Group LLC (2.13%) and Palisade Capital Management LLC NJ (1.74%). Company insiders that own Repligen stock include Anthony Hunt, Howard Benjamin, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.
Which major investors are selling Repligen stock?
RGEN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Wells Fargo & Company MN, Allianz Asset Management GmbH, Sei Investments Co., Citigroup Inc., RMB Capital Management LLC, Blair William & Co. IL and Schwab Charles Investment Management Inc.. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Howard Benjamin, Karen A Dawes, Nicolas Barthelemy, Roy T Eddleman and Thomas F Ryan Jr. View Insider Buying and Selling for Repligen.
Which major investors are buying Repligen stock?
RGEN stock was purchased by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Dimensional Fund Advisors LP, Russell Investments Group Ltd., Federated Investors Inc. PA, UBS Group AG, Pier Capital LLC, Cortina Asset Management LLC and Palisade Capital Management LLC NJ. View Insider Buying and Selling for Repligen.
How do I buy shares of Repligen?
Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repligen's stock price today?
One share of RGEN stock can currently be purchased for approximately $42.21.
How big of a company is Repligen?
Repligen has a market capitalization of $1.86 billion and generates $141.24 million in revenue each year. The biotechnology company earns $28.35 million in net income (profit) each year or $0.69 on an earnings per share basis. Repligen employs 476 workers across the globe.
How can I contact Repligen?
Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]
MarketBeat Community Rating for Repligen (RGEN)
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Repligen (NASDAQ:RGEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Repligen in the last 12 months. Their average twelve-month price target is $44.5714, suggesting that the stock has a possible upside of 5.59%. The high price target for RGEN is $50.00 and the low price target for RGEN is $40.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.86 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $44.5714 | $44.5714 | $44.5714 | $45.00 |
| Price Target Upside: | 5.59% upside | 28.89% upside | 28.89% upside | 29.61% upside |
Repligen (NASDAQ:RGEN) Consensus Price Target History
Repligen (NASDAQ:RGEN) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Repligen (NASDAQ:RGEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Repligen (NASDAQ RGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 88.22%
Repligen (NASDAQ RGEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/21/2018 | Anthony Hunt | CEO | Sell | 16,249 | $42.53 | $691,069.97 | 243,144 |  |
| 5/16/2018 | Roy T Eddleman | Major Shareholder | Sell | 118,850 | $42.07 | $5,000,019.50 | | |
| 5/11/2018 | Karen A Dawes | Director | Sell | 20,000 | $41.80 | $836,000.00 | 114,957 | |
| 5/9/2018 | Nicolas Barthelemy | Director | Sell | 26,500 | $40.54 | $1,074,310.00 | 27,988 | |
| 5/9/2018 | Roy T Eddleman | Major Shareholder | Sell | 120,000 | $40.62 | $4,874,400.00 | | |
| 3/8/2018 | Thomas F Ryan Jr | Director | Sell | 4,696 | $36.16 | $169,807.36 | 9,700 | |
| 1/22/2018 | Anthony Hunt | CEO | Sell | 8,970 | $35.95 | $322,471.50 | 83,613 | |
| 12/14/2017 | Howard Benjamin | VP | Sell | 12,729 | $35.34 | $449,842.86 | 36,554 | |
| 3/21/2017 | Karen A Dawes | Director | Sell | 2,521 | $34.12 | $86,016.52 | 95,764 | |
| 3/20/2017 | Howard Benjamin | VP | Sell | 12,216 | $34.62 | $422,917.92 | 36,124 | |
| 3/20/2017 | Thomas F Ryan Jr | Director | Sell | 4,000 | $34.83 | $139,320.00 | 12,594 | |
| 3/17/2017 | Jon Snodgres | CFO | Sell | 1,909 | $34.91 | $66,643.19 | 23,789 | |
| 11/28/2016 | Anthony Hunt | CEO | Sell | 5,000 | $33.12 | $165,600.00 | 68,342 | |
| 9/14/2016 | Thomas F Ryan Jr | Director | Sell | 2,700 | $32.58 | $87,966.00 | 9,394 | |
| 6/30/2016 | Thomas F Ryan Jr | Director | Sell | 5,000 | $26.60 | $133,000.00 | 12,094 | |
| 6/28/2016 | Thomas F Ryan Jr | Director | Sell | 10,000 | $24.59 | $245,900.00 | 27,094 | |
| 5/11/2016 | Howard Benjamin | VP | Sell | 2,889 | $26.72 | $77,194.08 | 18,626 | |
| 6/9/2015 | Howard Benjamin | VP | Sell | 35,000 | $38.14 | $1,334,900.00 | | |
| 5/11/2015 | Walter C Herlihy | CEO | Sell | 104,569 | $37.94 | $3,967,347.86 | | |
| 5/8/2015 | Thomas F Ryan Jr | Director | Sell | 20,000 | $37.19 | $743,800.00 | | |
| 3/23/2015 | Walter C Herlihy | CEO | Sell | 24,536 | $31.78 | $779,754.08 | | |
| 3/19/2015 | James R Rusche | SVP | Sell | 14,650 | $33.30 | $487,845.00 | | |
| 3/19/2015 | Thomas F Ryan Jr | Director | Sell | 10,000 | $32.62 | $326,200.00 | | |
| 3/19/2015 | Walter C Herlihy | CEO | Sell | 49,695 | $33.08 | $1,643,910.60 | | |
| 3/18/2015 | Howard Benjamin | VP | Sell | 15,795 | $32.63 | $515,390.85 | | |
| 11/19/2014 | Walter C Herlihy | CEO | Sell | 51,386 | $23.43 | $1,203,973.98 | | |
| 11/13/2014 | Thomas F Ryan Jr | Director | Sell | 10,000 | $23.81 | $238,100.00 | | |
| 11/11/2014 | Howard Benjamin | VP | Sell | 30,000 | $23.56 | $706,800.00 | | |
| 11/10/2014 | Michael A Griffith | Director | Sell | 23,342 | $22.90 | $534,531.80 | | |
| 8/13/2014 | Howard Benjamin | VP | Sell | 40,000 | $20.34 | $813,600.00 | | |
| 6/27/2014 | Thomas F Ryan Jr | Director | Sell | 10,000 | $22.41 | $224,100.00 | | |
| 6/24/2014 | Thomas F Ryan Jr | Director | Sell | 10,000 | $21.78 | $217,800.00 | | |
| 6/11/2014 | Walter C Herlihy | CEO | Sell | 60,335 | $20.11 | $1,213,336.85 | | |
| 6/9/2014 | James R Rusche | SVP | Sell | 30,000 | $20.19 | $605,700.00 | | |
| 6/6/2014 | Daniel P Witt | SVP | Sell | 47,709 | $20.56 | $980,897.04 | | |
| 4/15/2014 | Daniel P Witt | SVP | Buy | 10,000 | $3.05 | $30,500.00 | | |
| 8/8/2013 | James R Rusche | SVP | Sell | 30,000 | $10.01 | $300,300.00 | | |
| 6/21/2013 | Karen A Dawes | Director | Buy | 1,000 | $7.70 | $7,700.00 | | |
| 5/17/2013 | Thomas F Ryan Jr | Director | Sell | 21,000 | $8.97 | $188,370.00 | | |
| 5/15/2013 | Thomas F Ryan Jr | Director | Sell | 86,039 | $9.01 | $775,211.39 | | |
| 5/15/2013 | Walter C Herlihy | CEO | Sell | 40,000 | $8.97 | $358,800.00 | | |
| 9/21/2012 | Glenn L Md Cooper | Director | Buy | 10,000 | $6.09 | $60,900.00 | | |
| 8/16/2012 | Michael A Griffith | Director | Buy | 2,000 | $4.88 | $9,760.00 | | |
(Data available from 1/1/2013 forward)
Repligen (NASDAQ RGEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Anthony Hunt Sells 16,249 Shares of Repligen (RGEN) Stock
www.americanbankingnews.com - May 22 at 7:28 PM |
| Repligen (RGEN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 19 at 10:57 AM |
| Roy T. Eddleman Sells 118,850 Shares of Repligen (RGEN) Stock
www.americanbankingnews.com - May 18 at 1:33 PM |
| Repligen (RGEN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 11:09 AM |
 | Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
finance.yahoo.com - May 17 at 8:11 AM |
 | Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
feeds.benzinga.com - May 17 at 7:49 AM |
| Q3 2018 EPS Estimates for Repligen Reduced by First Analysis (RGEN)
www.americanbankingnews.com - May 16 at 7:24 AM |
| Repligen (RGEN) Director Sells $836,000.00 in Stock
www.americanbankingnews.com - May 15 at 10:29 AM |
| Repligen (RGEN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - May 15 at 12:36 AM |
| Nicolas Barthelemy Sells 26,500 Shares of Repligen (RGEN) Stock
www.americanbankingnews.com - May 11 at 1:23 PM |
| Q4 2018 EPS Estimates for Repligen (RGEN) Cut by Jefferies Group
www.americanbankingnews.com - May 11 at 10:52 AM |
| Edited Transcript of RGEN earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:11 AM |
| Repligen to Post Q2 2018 Earnings of $0.20 Per Share, Jefferies Group Forecasts (RGEN)
www.americanbankingnews.com - May 10 at 6:37 AM |
| Insider Selling: Repligen (RGEN) Major Shareholder Sells 120,000 Shares of Stock
www.americanbankingnews.com - May 9 at 7:15 PM |
| Novavax (NVAX) & Repligen (RGEN) Head to Head Analysis
www.americanbankingnews.com - May 8 at 9:09 PM |
 | Repligen's (RGEN) CEO Tony Hunt on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:51 PM |
| Repligen (RGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 8 at 2:43 PM |
| Repligen (RGEN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 8:56 AM |
 | Repligen (RGEN) Tops Q1 EPS by 2c, Beats on Revenues; Boosts FY18 EPS/Revenue Outlook
www.streetinsider.com - May 8 at 8:07 AM |
| Repligen beats by $0.02, beats on revenue
seekingalpha.com - May 8 at 8:07 AM |
| Repligen: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:07 AM |
| Repligen Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:07 AM |
| Zacks: Analysts Anticipate Repligen (RGEN) Will Announce Quarterly Sales of $43.88 Million
www.americanbankingnews.com - May 8 at 1:48 AM |
| Repligen (RGEN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 3:46 AM |
| Analysts Expect Repligen (RGEN) to Announce $0.15 Earnings Per Share
www.americanbankingnews.com - May 6 at 11:16 PM |
| Repligen to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 30 at 5:20 PM |
| Repligen (RGEN) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 26 at 9:48 AM |
| Repligen (RGEN) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:56 AM |
| $43.88 Million in Sales Expected for Repligen (RGEN) This Quarter
www.americanbankingnews.com - April 21 at 1:58 AM |
| $0.15 EPS Expected for Repligen (RGEN) This Quarter
www.americanbankingnews.com - April 19 at 9:22 PM |
| Repligen (RGEN) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 9:17 PM |
 | Repligen (RGEN) Shares Cross Above 200 DMA
www.nasdaq.com - April 12 at 5:51 PM |
| My Investing Horror Story: Selling too Early
finance.yahoo.com - April 12 at 8:13 AM |
| Repligen (RGEN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 3:52 AM |
| Repligen (RGEN) Raised to Overweight at First Analysis
www.americanbankingnews.com - April 8 at 3:17 PM |
| Repligen Co. (RGEN) Expected to Post Quarterly Sales of $43.88 Million
www.americanbankingnews.com - April 4 at 1:56 AM |
| Should You Be Tempted To Sell Repligen Corporation (NASDAQ:RGEN) Because Of Its PE Ratio?
finance.yahoo.com - April 3 at 5:42 PM |
| Zacks: Brokerages Anticipate Repligen Co. (RGEN) Will Announce Earnings of $0.15 Per Share
www.americanbankingnews.com - April 2 at 11:19 PM |
| Repligen (RGEN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 29 at 3:36 PM |
| Repligen (RGEN) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:48 PM |
| Repligen Corporation (NASDAQ:RGEN): Is It A Good Long Term Opportunity?
finance.yahoo.com - March 27 at 8:16 AM |
| Repligen (RGEN) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - March 25 at 9:50 AM |
| William Blair Weighs in on Repligen Co.'s Q1 2019 Earnings (RGEN)
www.americanbankingnews.com - March 21 at 10:58 AM |
| Repligen Co. (RGEN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 3:42 AM |
| Analysts Anticipate Repligen Co. (RGEN) Will Post Quarterly Sales of $43.88 Million
www.americanbankingnews.com - March 18 at 1:56 AM |
| Will Repligen Corporation’s (NASDAQ:RGEN) Earnings Grow In The Year Ahead?
finance.yahoo.com - March 16 at 6:37 PM |
| Repligen Co. Expected to Earn FY2020 Earnings of $0.98 Per Share (RGEN)
www.americanbankingnews.com - March 15 at 2:25 PM |
| Repligen (RGEN) Upgraded by TheStreet to "B-"
www.americanbankingnews.com - March 15 at 1:00 PM |
| William Blair Weighs in on Repligen Co.'s Q1 2018 Earnings (RGEN)
www.americanbankingnews.com - March 14 at 7:20 AM |
| Repligen Co. (RGEN) Director Sells $169,807.36 in Stock
www.americanbankingnews.com - March 12 at 7:57 PM |
Repligen (NASDAQ:RGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Repligen (NASDAQ:RGEN) Income Statement, Balance Sheet and Cash Flow Statement
Repligen (NASDAQ RGEN) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
